Publications

Search our bibliography using the filters on the right-hand side.

Displaying 51 through 100 of 104 publications.

Braun L, Sood V, Hogue S, Lieberman B, Copley-Merriman C. High burden and unmet patient needs in chronic kidney disease. Int J Nephrol Renovasc Dis. 2012 Dec 1;5:151-63.

Mauskopf J, Beach W, McIntyre L, Bhattacharyya S, Higgins L, Mordin M, Copley-Merriman K. Evidence-based medicine: a case study of its application to innovative surgical procedures in the United Kingdom. Poster presented at the 2012 ISPOR 15th Annual European Congress; November 7, 2012. Berlin, Germany. [abstract] Value Health. 2012 Nov; 15(7):A408.

Kiladjian JJ, Gisslinger H, Passamonti F, Neiderwieser D, Medelson E, Sirulnik LA, Copley-Merriman K, Zhou X. Health-related quality of life (HRQoL) and symptom burden in patients (Pts) with myelofibrosis (MF) in the COMFORT-II study. Poster presented at the European School of Haematology (ESH) International Conference on Myeloproliferative Neoplasms; October 4, 2012. Previously presented at the 2012 Annual Meeting of the American Society of Clinical Oncology (ASCO).

Kiladjian JJ, Gisslinger H, Passamonti F, Niederwieser D, Mendelson E, Sirulnik LA, Copley-Merriman K, Zhou X, Levy R, Knoops L, Cervantes F, Barbui T, Barosi G, Vannucchi A, Harrison C. Health-related quality of life (HRQoL) and symptom burden in patients (Pts) with myelofibrosis (MF) in the COMFORT-II study. Poster presented at the 17th Congress of the European Hematology Association; June 14, 2012. Amsterdam, the Netherlands. [abstract] Haematologica. 2012 Jul 16; 97(s1):154-5. Previously presented at the 2012 Annual Meeting of the American Society of Clinical Oncology (ASCO).

Kiladjian J-J, Gisslinger H, Passamonti F, Niederwieser D, Mendelson E, Sirulnik LA, Copley-Merriman K, Zhou X, Levy RS, Knoops L, Cervantes F, Barbui T, Barosi G, Vannucchi AM, Harrison CN. Health-related quality of life (HRQoL) and symptom burden in patients (Pts) with myelofibrosis (MF) in the COMFORT-II study. Poster presented at the 2012 Annual Meeting of the American Society of Clinical Oncology (ASCO); June 1, 2012. Chicago, IL. [abstract] J Clin Oncol. 2012 Jun 1; 30(15_suppl):6626. doi: 10.1200/jco.2012.30.15_suppl.6626

DeMuro C, Clark M, Mordin M, Fehnel S, Copley-Merriman C, Gnanasakthy A. Reasons for rejection of patient-reported outcome label claims: a compilation based on a review of patient-reported outcome use among new molecular entities and niologic license applications, 2006-2010. Value Health. 2012 May 1;15(3):443-8.

Harrison CN, Kiladjian J-J, Al-Ali H-K, Gisslinger H, Knoops L, Waltzman RJ, Copley-Merriman K. Health-related quality of life and symptoms in myelofibrosis patients treated with ruxolitinib versus best available therapy. Presented at the European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes; May 2012.

Gnanasakthy A, Mordin M, Clark M, DeMuro C, Fehnel S, Copley-Merriman C. A review of patient-reported outcome labels in the United States: 2006 to 2010. Value Health. 2012 May;15(3):437-42. doi: 10.1016/j.jval.2011.11.032

Zhou X, Wang J, Zhang J, Copley-Merriman K, Torigoe Y, Reyes C. Symptoms and toxicity of rituximab maintenance (R-M) versus observation (OBS) following rituximab plus chemotherapy in patients with follicular lymphoma. Poster presented at the 53rd American Society of Hematology (ASH) Annual Meeting and Exposition; December 2011. San Diego, CA. [abstract] Blood. 2011 Nov 18; 118(21):3661. doi: 10.1182/blood.V118.21.3661.3661

Kiladjian J, Al-Ali H, Gisslinger H, Knoops L, Waltzman RJ, Mendelson E, Copley-Merriman K. Health-related quality of life and symptoms in myelofibrosis patients treated with ruxolitinib versus best available therapy. Poster presented at the 53rd American Society of Hematology (ASH) Annual Meeting and Exposition; December 2011. San Diego, CA. [abstract] Blood. 2011 Nov 18; 118(21):795. doi: 10.1182/blood.V118.21.795.795

Walter JW, Spinner DS, Birt J, Bowman L, Mauskopf JA, Drummond M, Copley-Merriman K. Clinical and economic evidence bases for health technology assessment: a comparison of three jurisdictions. Poster presented at the 2011 ISPOR 14th Annual European Congress; November 2011. Madrid, Spain.

Sood V, Braun L, Hogue S, Davis K, Copley-Merriman C, Lieberman B. Chronic kidney disease burdens patients, health care systems, and employers. Poster presented at the 2011 ISPOR 14th Annual European Congress; November 9, 2011. [abstract] Value Health. 2011 Nov; 14(7):A331.

Nelson LM, Nixon A, Copley-Merriman K. Documenting PRO evidence for regulatory submissions to support labeling claims. Poster presented at the International Society for Quality of Life Research Workshop #2; October 2011.

Mauskopf J, Walter J, Birt J, Bowman L, Copley-Merriman C, Drummond M. Differences among formulary submission guidelines: implications for health technology assessment. Int J Technol Assess Health Care. 2011 Jul 1;27(3):261-70.

Mordin M, Clark M, DeMuro C, Evans ED, Copley-Merriman K, Fehnel S, Gnanasakthy A. Pro label claims: an analysis based on a review of pros among new molecular entities and biologic license applications 2006-2010. Poster presented at the 2011 ISPOR 16th Annual International Meeting; June 3, 2011. [abstract] Value Health. 2011 May; 14(3):A29.

DeMuro C, Mordin M, Evans ED, Copley-Merriman K, Fehnel S, Gnanasakthy A. Reasons for rejection of PRO label claims: an analysis based on a review of PRO use among new molecular entities and biologic license applications 2006–2010. Poster presented at the 2011 ISPOR 16th Annual International Meeting; June 3, 2011. [abstract] Value Health. 2011 May; 14(3):A29.

Coleman C, Chang S, Copley-Merriman K, Masaquel CJ, Hubble J. Health-related quality-of-life improvements with dysport in cervical dystonia. Poster presented at the 2011 ISPOR 16th Annual International Meeting; May 26, 2011. [abstract] Value Health. 2011 May; 14(3):A210.

Colosia AD, Peltz G, Pohl G, Liu E, Copley-Merriman K, Khan S, Kaye JA. A review and characterization of the various perceptions of quality cancer care. Cancer. 2011 Mar 1;117(5):884-96.

Norquist J, Nixon A, Copley-Merriman K. Documenting PRO evidence for EMA and FDA submissions to support promotional and labeling claims. Poster presented at the International Society for Quality of Life Research Workshop #12; October 2010.

Khan SB, Peltz G, Pohl G, Liu E, Copley-Merriman K, Colosia AD. Impact of patient/provider communications on quality of care for cancer. Poster presented at the 3rd Conference of the American Association for Cancer Research; October 2010.

Copley-Merriman K, Peltz G, Pohl G, Liu E, Kaye JA. Impact of race/ethnicity and health insurance status on quality of care for cancer. Poster presented at the Annual Meeting of the American Society of Clinical Oncology; June 2010.

Mordin MM, Lewis SA, Gnanasakthy A, DeMuro-Mercon CJ, Copley-Merriman K, Fehnel SE. Patient-reported outcomes in product development guidance. Poster presented at the 2010 ISPOR 15th Annual International Meeting; May 1, 2010. Atlanta, GA. [abstract] Value Health. 2010 May; 13(3):A-17-8.

Mordin M, Lewis SE, Gnanasakthy A, Demuro-Mercon C, Copley-Merriman K, Fehnel S. Patient-reported outcomes as mentioned in product development guidance. Poster presented at the 2010 ISPOR 15th Annual International Meeting; May 4, 2010. [abstract] Value Health. 2010 May; 13(3):A17-8.

Gnanasakthy A, DeMuro C, Mordin M, Copley-Merriman K, Mauskopf J. The role of the patient voice in health technology assessment. Poster presented at the 2010 ISPOR 15th Annual International Meeting; May 2010. Atlanta, GA. [abstract] Value Health. 2010 May; 13(3):A19. doi: 10.1016/S1098-3015(10)72074-X

Nelson LM, Copley-Merriman K, Norquist J, Powers J. PRO evidence dossier: evidence to support labeling and promotional claims for FDA-regulated medicine products. Poster presented at the International Society for Quality of Life Research Workshop #3; October 2009.

Arbuckle R, Clark M, Harness J, Bonner N, Scott J, Draelos Z, Rizer R, Yeh Y, Copley-Merriman K. Item reduction and psychometric validation of the oily skin self assessment scale (OSSAS) and the oily skin impact scale (OSIS). Value Health. 2009 Jul 1;12(5):828-37.

Copley-Merriman K, Barrows SM, Whiteley J, Barrett AM. Value messages: developing, incorporating, and making use of a core strategic tool. Poster presented at the 2009 ISPOR 14th Annual International Meeting; May 28, 2009.

Copley-Merriman K, Barrett AM, Barrows SM, Whiteley J. Understanding and transmitting the value of a new drug. Poster presented at the International Society for Pharmacoeconomics and Outcomes Research 14th Annual International Meeting; May 15, 2009.

Mordin MM, Clark M, Siersma CA, Copley-Merriman K, Gnanasakthy A. Impact of the FDA draft guidance on patient reported outcomes (PRO) label claims for approved drug products in the US: has it made a difference? Poster presented at the International Society for Pharmacoeconomics and Outcomes Research 14th Annual International Meeting; May 19, 2009. Orlando, FL. [abstract] Value Health. 2009 May; 12(3):A29.

Arbuckle R, Atkinson M, Clark MJ, Abetz-Webb L, Lohs J, Kuhagen I, Harness J, Draelos Z, Thiboutot D, Blume-Paytavi U, Copley-Merriman K. Patient experiences with oily skin: the qualitative development of content for two new patient reported outcome questionnaires. Poster presented at the American Academy of Dermatology Meeting; March 1, 2009.

Harness J, Draelos Z, Thiboutot D, Blume-Paytavi U, Mamolo C, Arbuckle R, Atkinson M, Clark M, Abetz L, Lohs J, Kuhagen I, Copley-Merriman K. Patient experiences with oily skin: the development of two new patient- reported outcomes questionnaires. Presented at the Annual Meeting of the American Academy of Dermatology; March 2009. San Francisco, CA.

Mamolo C, Harness J, Arbuckle R, Bonner N, Clark MJ, Scott J, Copley-Merriman K. Psychometric validation of the oily skin self-assessment and the oily skin impact scale (OSIS). Poster presented at the American Academy of Dermatology Meeting; March 1, 2009.

Mladsi DM, Irish WD, Copley-Merriman K, Bhandary D. Statistical measures of treatment effects in oncology: what are we missing? Presented at the 2008 ISPOR 11th Annual European Congress; November 2008. Athens, Greece.

Arbuckle R, Atkinson MJ, Clark M, Abetz L, Lohs J, Kuhagen I, Harness J, Draelos Z, Thiboutot D, Blume-Peytavi U, Copley-Merriman K. Patient experiences with oily skin: the qualitative development of content for two new patient reported outcome questionnaires. Health Qual Life Outcomes. 2008 Oct 16;6:80. doi: 10.1186/1477-7525-6-80.

Copley-Merriman C, Fehnel SE, Chandler J, Wild D. Obtaining a patient-reported outcomes label claim: what evidence do you need? Poster presented at the 2008 ISPOR 13th Annual International Meeting; May 7, 2008.

Offen W, Chuang-Stein C, Dmitrienko A, Copley-Merriman K. Multiple co-primary endpoints: medical and statistical solutions: a report from the multiple endpoints expert team of the PhRMA. Drug Inf J. 2007;4:31-46.

Evans C, Katz N, Simon L, Bombardier C, West C, Robbins J, Copley-Merriman K, Coombs J. Development and preliminary validation of a responder index for patients with chronic low back pain. J Pain. 2006 Apr;7(4 (Supplement)):S84. doi: 10.1016/j.jpain.2006.01.341

Abetz L, Coombs JH, Keininger DL, Earle CC, Wade C, Bury-Maynard D, Copley-Merriman K, Hsu MA. Development of the cancer chemotherapy satisfaction questionnaire (CCSQ): item generation and content validity testing. Value Health. 2005 Nov;8(Suppl 1):S41-53.

Copley-Merriman K, Jackson J, Boyer JG, Cappelleri J, DeMarinis R, DiCesare J. Industry perspective regarding outcomes research in oncology. New York: NY. Cambridge University Press; 2004. p.623-38.

Shah S, Sesti AM, Copley-Merriman K, Plante M. Quality of life terminology included in package inserts for US approved medications. Qual Life Res. 2003 Dec 1;12(8):1107-17.

Dorazio P, Keininger DL, Abetz L, Coombs JH, Copley-Merriman K, Bury-Maynard DP, Hsu MA. Comparing patient and nurse perspectives on cancer treatment: results from a qualitative study. Poster presented at the 39th Annual Meeting of the American Society of Clinical Oncology; September 2003. Chicago, IL. [abstract] American Society Of Clinical Oncology Meeting Proceedings. 2003 Sep; 22:778.

Coombs JH, Abetz L, Keininger DL, Earle CC, Copley-Merriman K, Hsu M-A, Bury-Maynard DP. Development of the Cancer Chemotherapy Satisfaction Questionnaire (CCSQ): part I: item-generation and content validity testing. Poster presented at the 39th Annual Meeting of the American Society of Clinical Oncology; May 2003. Chicago, IL. [abstract] American Society Of Clinical Oncology Meeting Proceedings. 2003 May; 22:545.

Osoba D, Hsu M-A, Copley-Merriman K, Johnson FR, Hauber AB, Coombs J. Cancer patients' preferences for health-related quality of life (HRQOL) domains during treatment. Poster presented at the 2003 Annual Meeting of the American Society of Clinical Oncology; May 2003.

Clark M, Copley-Merriman K, Coombs JH, Von Pawel J, Koschel G, Pauer LR. Patient reported outcomes (symptoms, functioning, and quality of life [QOL]) in a randomized Phase II study of CI-994 plus carboplatin and paclitaxel (C/T) vs placebo (PBO) plus C/T in the first-line treatment of patients with advanced nonsmall cell lung cancer (NSCLC). Poster presented at the 39th Annual Meeting of the American Society of Clinical Oncology; May 2003. Chicago, IL. [abstract] American Society Of Clinical Oncology Meeting Proceedings. 2003 May; 22:687.

McBurney C, Coombs J, Hsu M, Abetz L, Keininger D, Copley-Merriman K. An appraisal of treatment satisfaction and patient preference assessments in patients diagnosed with cancer. Poster presented at the International Society for Pharmacoeconomics and Outcomes Research; 2003. [abstract] Value Health. 5(3):201.

Coombs J, McBurney C, Gondek K, Copley-Merriman C. Evidence of patient reported outcomes in labeling for oncology products: evaluation of United States and European labels. Mapi Quality of Life Newsletter. 2002 Oct;29:1-3.

Salerno DF, Copley-Merriman C, Taylor TN, Shinogle J, Schulz RM. A review of functional status measures for workers with upper extremity disorders. Occup Environ Med. 2002 Oct;59(10):664-70.

Copley-Merriman K, Pawel J, Shepard F, Kimmel K, Gulyas S, Eckert S. Randomized phase 2 study of the oral histone deacetylase inhibitor ci-994 plus gemcitabine vs. placebo plus gemcitabine in second-line nsclc: health-related quality of life results. Poster presented at the American Society of Clinical Oncology; May 2002. Orlando, FL.

Shah S, Sesti AM, Copley-Merriman K, Clark M. Summary of quality of life labeling components in the package inserts. Poster presented at the DIA-QOL Meeting; March 2002.

Santanello NC, Baker D, Cappelleri JC, Copley-Merriman K, DeMarinis R, Gagnon JP, Hsuan A, Jackson J, Mahmoud R, Miller D, Morgan M, Osterhaus J, Tilson H, Willke R. Regulatory issues for health-related quality of life—PhRMA Health Outcomes Committee Workshop, 1999. Value Health. 2002 Jan;5(1):14-25.